Gomarara ndiro riri kukonzera rufu munyika yose uye rinofungidzirwa kuti richakwira nekufa kwevanhu vanosvika miriyoni gumi nemazana mashanu muna 11.5. Gomarara rinonyanya kufarirwa nekenza yemapapu, rinosvika mamiriyoni 2030 ekufa, mamwe marudzi egomarara anosanganisira kenza yechiropa, kenza yemazamu, yemudumbu. kenza yechiropa, etc. Kenza inogona kurapwa nekuvhiyiwa, chemotherapy, radiation therapy, hormone therapy, targeted therapy, precision medicine, immunotherapy uye stem cell transplantation. Immunotherapy inosanganisira kushandisa immune system yemunhu kurwisa cancer; zvinosanganisira kukurudzirwa kwemasimba ekudzivirira zvirwere kurwisa masero emukenza kana kupa masimba ezvirwere zvemuviri nemaitiro evanhu.
Mhando dzakasiyana dze immunotherapy dzinosanganisira monoclonal antibodies, yakagadzirirwa kurwisa masero chaiwo; immune checkpoint inhibitors, mishonga inoziva nekurwisa maseru egomarara nekubvisa mabhureki eT cell; majekiseni egomarara, anoshandiswa kukonzeresa mhinduro yekudzivirira kurwisa chirwere uye mamwe akasiyana-siyana asiri chaiwo immunotherapy anoshandiswa kuwedzera immune system. Radioimmunotherapy ndiyo musanganiswa weradiation therapy uye immunotherapy. Monoclonal masoja ekudzivirira chirwere anogadzirwa murabhoritari uye akabatanidzwa neradioactive material inonzi radiotracers. Kana yaiswa jekiseni, redhiyo yakanzi antibody kuti isungirire kune chaiyo cancer cell uye yakaparadza sero regomarara neradioactivity yayo. Iyo radioactive agents anoshandiswa zvakanyanya ndeye Yttrium-90 Ibritumomab Tiuxetan, Iodine-131 Tositumomab, nevamwe.
Kuti urambe uri 'mberi' kwevakwikwidzi vako, kumbira a bhurocha: https://www.futuremarketinsights.com/reports/brochure/rep-gb-3701
Miedzo yakawanda yekiriniki irikuenderera mberi yekumisikidza kugona kweredhiyo yakanyorwa kuti monoclonal antibody. Radioimmunotherapy inoshandiswawo kurapa varwere vanorwara ne-non-Hodgkin B-cell lymphoma, uye mamwe madiki-emhando dze lymphoma kana varwere vasingadaire kune chemotherapy. Kazhinji, hapana mhedzisiro inoonekwa panguva yekurapa. Mundima yekiriniki, zvidzidzo zvekiriniki zvinoitwa kuwedzera biological uye kemikari kushanda uye kurapwa maitiro ekuvandudza muradioimmunotherapy. Nzira dzese dzakananga uye dzisina kunanga dzinoshandiswa mukuunza radioimmunotherapy mamorekuru. Kuwedzera discretionary mari yekutsvagisa cancer nehurumende nemasangano emubatanidzwa, kuwedzera kweMedicare kufukidzwa, kuwedzera kuwanda kwegomarara pakati pehuwandu hwevanhu vari kukura, kuwanikwa kwekurapwa kwegomarara kutsva, uye zvimwe zvinhu zvakasiyana zvichasimudzira musika weradioimmunotherapy munguva pfupi iri kutevera.
Radioimmunotherapy Kurapa Musika: Vatyairi uye Zvinodzora
Sekureva kweWord Health Organisation, zvinofungidzirwa kuti panosvika gore ra2030, vanhu vanosvika 23.6 miriyoni vegomarara vachange vabata pasi rose. Nhungamiro yehurumende kubva kuAmerican Society of Clinical Oncology uye National Comprehensive Cancer Network (NCCN/ASCO) iri kupa rubatsiro kuvashandi vehutano mukutarisira uye kurapwa kwevarwere vegomarara. Kutsvagisa kwakasimba uye kusimukira mukurapa cancer, kukwira kwezviitiko zvekenza, kwakawedzera kufarira kutsvagiro yegomarara. Muna Kubvumbi 2016, Hurumende yeUS yakapa US$5.2 Bn yeNational Cancer Institute (NCI), bazi rehurumende yemubatanidzwa, yekutsvaga cancer uye kudzidzisa. Bhajeti yakawedzera ne5.3% kana zvichienzaniswa negore rapfuura. Inishuwarenzi yekuvhara uye nyaya dzekudzosera mari, makambani makuru ari kuisa mari yakawanda mukurapa kenza inosanganisira nguva nemari, uye hapana vimbiso yekuti chigadzirwa chichawana kufukidzwa, njodzi yemwaranzi kune vashandi vehutano nevarwere zvimwe zvinhu zvinogona kuderedza kukura kweredhiyo. -immunotherapy musika
Radioimmunotherapy Kurapa Musika: Pfupiso
Kubva pamhando yezvinodhaka, pasi rose radioimmunotherapy kurapwa musika yakakamurwa kuita ibritumomab, tositumomab, rituximab, epratuzumab, lintuzumab, labetuzumab uye trastuzumab. Pahwaro hwemaitiro emhando iyo radioimmunotherapy kurapwa musika yakakamurwa kuita yakananga uye isina kunanga nzira. O Pahwaro hwechiratidzo chechirwere, musika wakakamurwa kuita isiri-hodgkin lymphoma, myeloid leukemia, colorectal cancer, cancer yemazamu, akawanda myeloma nevamwe. Zvichienderana nemushandisi wekupedzisira, musika wakakamurwa kuita chipatara, ambulatory yekuvhiya nzvimbo uye cancer research Institute. Kukwira kwehuwandu hwevarwere vegomarara, mari nemasangano ehurumende, inotarisa pakutora uye kubatanidzwa nevagadziri vakasiyana-siyana vakakosha kunokonzerwa nekukura kwemusika weradio-immunotherapy.
Radioimmunotherapy Kurapa Musika: Yedunhu Overview
Dunhu nehungwaru, iyo yepasi rose Radioimmunotherapy Treatment Market yakakamurwa kuita matunhu anoti, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East uye Africa. Chikamu chinodarika makumi manomwe kubva muzana cherufu rwegomarara pasi rose chinoitika muAfrica, Asia neSouth America. Zvikamu makumi matatu nezvitatu kubva muzana zvegomarara pasi rose zvinokonzerwa nehutsi nefodya. Pamwe nekuwedzera mumisika iri kusimukira, uye kutarisisa kwekutanga kuongororwa, kuongorora, kutarisa uye kukura kwekiriniki kwakabatana neradiotherapy kurapwa kwave kuri nzira huru dzakatorwa nevatambi vakuru mumusika wepasi rose weradioimmunotherapy.
Radioimmunotherapy Kurapa Musika: Vatambi Vakakosha
Vamwe vevatambi vakakosha mumusika wepasi rose Radioimmunotherapy Treatment Market ndeye GlaxoSmithKline plc. Bayer AG, MabVax Therapeutics Holdings, Inc., Panacea Pharmaceuticals, Inc. Nordic Nanovector, Actinium Pharmaceuticals, Inc., Immunomedics, Inc., Spectrum Pharmaceuticals, Inc.nevamwe.
Chirevo chekutsvagisa chinopa ongororo yakazara yemusika uye ine pfungwa dzinofunga, chokwadi, nhoroondo yedata, uye inotsigirwa nenhamba uye indasitiri-yakasimbiswa musika data. Iine zvakare mafungidziro achishandisa seti yakakodzera yefungidziro uye nzira. Chirevo chekutsvagisa chinopa ongororo uye ruzivo zvinoenderana nemapoka akadai semusika zvikamu, geographies, rudzi rwechigadzirwa uye mashandisirwo.
Chirevo chinofukidza ongororo yakakwana pane:
- Zvikamu zveMusika
- Soko Dynamics
- Kukura Kwemusika
- Kupa & Kudiwa
- Maitiro Echazvino / Nyaya / Zvinetso
- Makwikwi & Makambani anobatanidzwa
- Technology
- Kukosha Chain
Kuongorora kwedunhu kunosanganisira
- North America (US, Canada)
- Latin America (Mexico, Brazil uye Zororo reLatin America)
- Western Europe (Germany, Italy, France, UK, Spain, Nordic countries, Belgium, Netherlands, Luxembourg neWestern Europe yese)
- Eastern Europe (Poland, Russia neKumabvazuva kweEurope)
- Asia Pacific (China, India, ASEAN, Australia neNew Zealand)
- Japani
- Middle East neAfrica (GCC, S. Africa, uye Zororo reMEA)
Chirevo ichi mubatanidzwa weruzivo rwekutanga-ruoko, hunhu uye huwandu hwekuongorora nevanoongorora maindasitiri, mapindiro kubva kunyanzvi dzeindasitiri uye vatori vechikamu mumaindasitiri mukati mekukosha kweketani. Chirevo chinopa kuongororwa kwakadzama kwemaitiro emusika wevabereki, macro-economic zviratidzo uye zvinhu zvinotonga pamwe nekukwezva kwemusika sezvikamu. Chirevo ichi zvakare chinomepu maitiro emhando dzakasiyana dzemusika zvinhu pamusika zvikamu uye geographies
Radioimmunotherapy Kurapa Musika: Segmentation
Musika wepasi rose weradioimmunotherapy kurapwa wakaiswa pahwaro hwemhando yezvinodhaka, maitiro emhando, chiratidzo chechirwere, chinangwa cherudzi uye geography.
Zvichienderana nerudzi rwezvinodhaka, musika weradioimmunotherapy wakakamurwa kuita zvinotevera:
- Ibritumomab
- Tositumomab
- Rituximab
- Epratuzumab
- Lintuzumab
- Labetuzumab
- Trastuzumab
- vamwe
Zvichienderana neRudzi rweNzira, musika wepasi rose radioimmunotherapy kurapwa wakakamurwa kuita zvinotevera:
- Direct Nzira
- Nzira isina kunanga
Kubva pane Chiratidzo Chirwere, musika wepasi rose radioimmunotherapy kurapwa wakakamurwa kuita zvinotevera:
- Asiri-Hodgkin lymphoma
- Myeloid leukemia
- Colorectal cancer
- zamu Cancer
- Multiel Myeloma
- vamwe
Zvichienderana neMushandisi Wekupedzisira, musika wepasi rose radioimmunotherapy kurapwa wakakamurwa kuita zvinotevera:
- Hospitals
- Ambulatory kuvhiya nzvimbo
- Cancer Research Institutes
- vamwe
Kuti uve nhanho imwe mberi, tora TOC yeChirevo ichi: https://www.futuremarketinsights.com/toc/rep-gb-3701
Taura Zvikuru:
- Detailed overview yemusika wevabereki
- Kuchinja kushanduka kwemusika muindasitiri
- Mukudzika kwemusika zvikamu
- Nhoroondo, yazvino uye yakafungidzirwa yemusika musika maererano nehuwandu uye kukosha
- Zvichangoburwa zveindasitiri maitiro uye kusimukira
- Competitive landscape
- Maitiro evatambi vakakosha uye zvigadzirwa zvinopihwa
- Zvinogoneka uye niche zvikamu, matunhu enzvimbo anoratidza kukura kunovimbisa
- Maonero asina kwaakarerekera pamashandiro emusika
- Inofanirwa-kuve neruzivo rwevatambi vemusika kuti vatsigire uye nekusimudzira musika wavo tsoka
Nezve Ramangwana Musika Kunzwisisa (FMI)
Future Market Insights (FMI) inotungamira mupi wehungwaru hwemusika uye masevhisi ekubvunzana, achishandira vatengi munyika dzinopfuura zana nemakumi mashanu. FMI inotungamirwa kuDubai, uye ine nzvimbo dzekutumira muUK, US neIndia. FMI ichangoburwa mishumo yekutsvagisa musika uye ongororo yeindasitiri inobatsira mabhizinesi kufamba mumatambudziko uye kuita sarudzo dzakakomba nekuvimba uye kujeka pakati pemakwikwi ebreakneck. Yedu yakagadziridzwa uye yakabatanidzwa yemusika mishumo yekutsvagisa inopa maitiro ekuona anofambisa kukura kwakasimba. Chikwata chevanoongorora-vanotungamirwa nenyanzvi paFMI chinoramba chichiteedzera mafambiro ari kubuda uye zviitiko muhuwandu hwakawanda hwemaindasitiri kuti ive nechokwadi chekuti vatengi vedu vanogadzirira zvinodiwa nevatengi vavo.
Taura nesu:
Ramangwana Musika Kunzwisisa
Chikamu Nhamba: AU-01-H Gold Tower (AU), Plot Nha: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Zvekutengesa Inquiries: [email inodzivirirwa]
ZveMedia Inquiries: [email inodzivirirwa]
Webhusaiti: https://www.futuremarketinsights.com
ZVOKUBVA MUNYAYA INO:
- Insurance coverage and reimbursement issues, big companies are investing heavily in the cancer therapeutics involving both time and money, and there is no guarantee that the product will get coverage, radiation risk to healthcare professionals and patients are some factors that may decline the growth of radio-immunotherapy market.
- Increasing discretionary funding for cancer research by government and federal agencies, increase in Medicare coverage, rising prevalence of cancer among growing population, availability of new cancer treatment, and various other factors are will booth the radioimmunotherapy market in the near future.
- The rise in cancer patient population, funding by the governmental bodies, focus on acquisition and merger by various key manufacturers is attributed towards the growth of radio-immunotherapy treatment market.
